
Inlyta 1mg Tablet
Marketer
Pfizer Ltd
Salt Composition
Axitinib (1mg)
Overview Inlyta 1mg Tablet
Axitinib 1mg tablets are prescribed for renal cell carcinoma. This anti-cancer medication may be administered with or without food, but consistent daily timing optimizes therapeutic effects. Dosage and frequency are determined by your physician based on your condition and may be adjusted. Adhere strictly to your doctor's instructions; improper usage or overdose can lead to severe adverse reactions. Benefits may not be apparent for weeks or months; discontinue use only as directed. Common side effects include hypertension, arthralgia, and anorexia. Diarrhea and dyspnea can be serious; address these with prescribed medication and/or hydration. Regular blood pressure monitoring is often recommended. Report severe headache, cognitive impairment, visual disturbances, nausea, or vomiting immediately. Prior to commencing treatment, disclose any thyroid disorders, hepatic or hemorrhagic conditions, or concurrent medications, particularly anti-infectives. Interactions with other drugs are possible; inform your healthcare provider of all medications. This medication is contraindicated during gestation and lactation; effective contraception is crucial for women undergoing treatment. A patient assistance program exists in India, managed by Tata 1mg. Consult your physician or call (1800-102-1618) for further information.
Uses of Inlyta 1mg Tablet
Renal cell carcinoma
Major Benefits of Inlyta 1mg Tablet:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the 1mg Inlyta tablet whole; avoid chewing, crushing, or breaking it. While it can be taken with or without food, consistency is key—take it at the same time each day.
Common Side effects of Inlyta 1mg Tablet:
- High blood pressure
- Joint pain
- Loss of appetite
- Diarrhea
- Breathing problems
- Abdominal pain
- Constipation
- Cough
- Decreased appetite
- Decreased level of thyroid hormones
- Difficulty in speaking
- Dry skin
- Indigestion
- Headache
- Nausea
- Pain in extremities
- Painful blisters on hands and feet
- Protein in urine
- Rash
- Breathlessness
- Stomatitis (Inflammation of the mouth)
- Taste change
- Vomiting
How to use Inlyta 1mg Tablet:
Follow your doctor's instructions precisely regarding the dosage and treatment length for this medication. Ingest the tablet whole; avoid chewing, crushing, or breaking it. Inlyta 1mg Tablets can be administered with or without food, although consistent timing is recommended.
How Inlyta 1mg Tablet works:
Inlyta 1mg tablets are an anticancer drug that inhibits the activity of a specific aberrant protein responsible for cancer cell proliferation, thus hindering or retarding tumor growth.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Inlyta 1mg Tablet may be unsafe; physician consultation is recommended.
PregnancyCONSULT YOUR DOCTOR
Using Inlyta 1mg tablets during pregnancy poses a confirmed risk to the fetus. Therefore, it's contraindicated. In exceptional, life-threatening circumstances, a physician might prescribe it if the potential benefits outweigh the known hazards. Always seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The use of Inlyta 1mg tablets while breastfeeding is likely inadvisable. Preliminary human evidence indicates potential transfer of the medication into breast milk, posing a risk to the infant.
DrivingUNSAFE
Taking a 1mg Inlyta tablet may cause drowsiness, blurred vision, and dizziness, potentially impairing alertness. Refrain from driving if these effects are experienced.
KidneySAFE IF PRESCRIBED
Patients with kidney disease can safely use Inlyta 1mg tablets without any necessary dosage modifications.
LiverCAUTION
Patients with liver impairment should use Inlyta 1mg tablets cautiously; dosage modification may be necessary. Physician consultation is advised. Data regarding Inlyta 1mg tablet use in patients with severe hepatic dysfunction are limited.
What if you forget to take Inlyta 1mg Tablet :
NA
Facts to Know About Inlyta 1mg Tablet
| Label | Value |
|---|---|
| Chemical Category | Indazole and Enzamide Derivatives |
| Developing Habits | No. |
| Treatment Category | Cancer Therapeutics |
| Action Class | Kinase inhibitors targeting tyrosine |
